Our Pipeline

Developing engineered oncolytic viruses and cell-based delivery platforms

Calidi Biotherapeutics has the opportunity to be first-to-market with patented proprietary approaches that have the potential to revolutionize the way that cancer is treated. The safety of Calidi’s proprietary treatment protocol, combining stem cells with oncolytic viruses, was established during the recently completed Phase I clinical trial with 25 patients. Calidi Biotherapeutics is currently seeking FDA approval for a Phase II clinical trial.

Calidi‘s proprietary engineered oncolytic viruses can be selectively programmed in a variety of ways, including: i) imaging to diagnose cancer, ii) delivering additional therapeutic agents, and iii) targeting cancer stem cells responsible for the cancer recurrence. There are multiple product lines in development to deliver a diverse range of anti-cancer and immune-modulatory agents.

Oncology

Molecule

SI-001 | (CAL1 VV + autologous cell)

SNe-01 | (CAL 1 VV + allogenic cell)

SNe-02 | (CAL 2 VV + allogenic cell)

SNe-03 | (Allogenic carrier cell for any oncolytic virus)

Potential Indicator

Solid Tumor

Solid Tumor

Solid Tumor

Solid Tumor

Phase

Phase 1 (Phase 3 of 5)

60%

Preclinical (Phase 2 of 5)

40%

Preclinical (Phase 2 of 5)

40%

Discovery (Phase 2 of 5)

20%

CAL1 = Naturally occurring attenuated vaccinia virus

CAL2 = Genetically modified CAL1 encoding Immunotherapeutic

CAL1 = Naturally occurring attenuated vaccinia virus
CAL2 = Genetically modified CAL1 encoding Immunotherapeutic

Phases of Trial: Discovery, Preclinical, Regulatory, Phase 1, Phase 1b/2